TY  - JOUR
AU  - Ruf, Theresa
AU  - Kramer, Rafaela
AU  - Forschner, Andrea
AU  - Leiter, Ulrike
AU  - Meier, Friedegund
AU  - Reinhardt, Lydia
AU  - Dücker, Pia
AU  - Ertl, Carolin
AU  - Tomsitz, Dirk
AU  - Tietze, Julia K
AU  - Gutzmer, Ralf
AU  - Dabrowski, Evelyn
AU  - Zimmer, Lisa
AU  - Gesierich, Anja
AU  - Zierold, Sarah
AU  - French, Lars E
AU  - Eigentler, Thomas
AU  - Amaral, Teresa
AU  - Heinzerling, Lucie
TI  - Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
JO  - European journal of cancer
VL  - 203
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2024-00849
SP  - 114028
PY  - 2024
AB  - Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10
KW  - Immune checkpoint inhibitors (Other)
KW  - Immune-related adverse events (Other)
KW  - Second-line immunosuppressants (Other)
KW  - Steroid-dependent (Other)
KW  - Steroid-refractory (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38652976
DO  - DOI:10.1016/j.ejca.2024.114028
UR  - https://inrepo02.dkfz.de/record/289667
ER  -